Literature DB >> 2628500

Serum levels of interleukin-2 in cancer patients: preliminary considerations.

P Lissoni1, S Viviani, A Santoro, S Barni, G Tancini.   

Abstract

In order to investigate the production of interleukin-2 (IL-2) in human neoplasms, we determined IL-2 and soluble IL-2 receptors (sIL-2R) in serum from 18 patients with lymphoma and 28 patients with solid tumors, with (15 cases) or without (13 cases) metastases. As controls, 58 healthy subjects were evaluated. Low levels of IL-2 were not observed in patients with lymphoma or limited solid tumor but abnormally low concentrations of IL-2 were seen in 4/15 metastatic solid tumors, associated with abnormally high values of sIL-2R. This preliminary study confirms in vivo the reduced IL-2 production in metastatic solid neoplasms, previously documented in vitro.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2628500     DOI: 10.1177/172460088900400404

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  2 in total

1.  Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients.

Authors:  Luca Degrate; Cinzia Nobili; Claudio Franciosi; Roberto Caprotti; Fernando Brivio; Fabrizio Romano; Biagio Eugenio Leone; Rosangela Trezzi; Franco Uggeri
Journal:  Langenbecks Arch Surg       Date:  2008-08-01       Impact factor: 3.445

2.  Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.

Authors:  L Fumagalli; P Lissoni; G Di Felice; S Meregalli; G Valsuani; S Mengo; F Rovelli
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.